Bronchocin® (Bronchocin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceGlaucin + Ephedrine + [Basil of common oil]Glaucin + Ephedrine + [Basil of common oil]
Similar drugsTo uncover
  • Broncholitin®
    syrup inwards 
    Sopharma, AO     Bulgaria
  • Bronchoton
    syrup inwards 
    VetProm AD     Bulgaria
  • Bronchocin®
    syrup inwards 
    Balkanfarm - Troyan AD     Bulgaria
    • Dosage form: & nbspsyrup
    Composition:
    Ingredients: 125 g of syrup contain:
    Active substances: glaucine hydrobromide 0.125 g; ephedrine hydrochloride 0.100 g; basil of ordinary oil 0.125 g. auxiliary substances: citric acid monohydrate 0.125 g, sucrose 43.750 g, polysorbate 80 1.375 g, methyl parahydroxybenzoate 0.150 g, propyl parahydroxybenzoate 0.025 g, ethanol (96 ° / o) 1.500 g, purified water up to 125,000 g.
    1 measuring spoon (5 ml) contains:
    Active substances: glaucine hydrobromide 5.75 mg; ephedrine hydrochloride 4.6 mg; basil of common oil 5.75 mg.
    Auxiliary substances: citric acid monohydrate 5.750 mg, sucrose 2012.500 mg, polysorbate 80 63.250 mg, methyl parahydroxybenzoate 6,900 mg, propyl parahydroxybenzoate 1,150 mg, ethanol (96%) 69,000 mg, water purified to 5,000 ml.
    Description:

    Viscous liquid from transparent to slightly opalescent from colorless to colorless with a yellowish tint of color with a characteristic smell of basil.

    Pharmacotherapeutic group:Antitussive drug combined (antitussive drug of central action + sympathomimetic)
    ATX: & nbsp

    R.05.D.B   Other antitussives

    R.05.D.B.20   Combined preparations

    Pharmacodynamics:

    BRONCHOZIN® is a combination drug with antitussive and bronchodilating action. It has a complex effect on the respiratory and central nervous system, which makes it a means of choice in the treatment of cough of various etiologies.

    Glaucine hydrobromide has an overwhelming effect on the center of the cough, without affecting breathing. It also has a weak bronchial and secretory effect.

    Ephedrine stimulates breathing, dilates the bronchi and, through vasoconstrictive action, reduces the swelling of their mucous membranes.

    Basil oil has sedative, anti-inflammatory, anesthetic and weak antiseptic effect.

    Pharmacokinetics:

    Glaucin and ephedrine well absorbed in the digestive tract, creating and maintaining the necessary therapeutic levels in blood plasma. They are allocated mainly through the kidneys.

    Indications:

    Complex therapy of diseases of the respiratory system accompanied by dry cough: acute inflammatory diseases of the upper respiratory tract, acute and chronic bronchitis, tracheobronchitis, chronic obstructive pulmonary disease, bronchial asthma,pneumonia, bronchiectasis, whooping cough.

    Contraindications:

    Hypersensitivity to the components of the drug, ischemic heart disease, coronary atherosclerosis, stenocardia, arterial hypertension, chronic heart failure, diabetes mellitus, thyrotoxicosis, pheochromocytoma, insomnia, angle-closure glaucoma, prostatic hypertrophy (with clinical symptoms), children's age (up to 6 years) , pregnancy (I trimester), the period of breastfeeding.

    Carefully:

    Patients with a tendency to develop drug dependence. Due to the content of ethanol, caution should be exercised in patients with liver disease, alcoholism, epilepsy, brain diseases, in children.

    Pregnancy and lactation:

    Bronchocin® should not be taken in the first trimester of pregnancy. Regardless of the fact that there is no data on embryotoxic and teratogenic effects, the use of the drug for pregnant women is possible only if the expected benefit for the mother exceeds the potential risk to the fetus or baby.

    Dosing and Administration:

    Inside.

    For adults - 2 scoops (10 ml) 3-4 times a day.

    Children from 6 to 10 years - 1 scoop (5 ml) 3 times a day.

    Children over 10 years - 2 measuring spoons (10 ml) 3 times a day.

    Side effects:

    From the cardiovascular system: tachycardia, extrasystole, increased blood pressure.

    From the nervous system: tremor, agitation, insomnia, dizziness.

    From the digestive system: nausea, vomiting, anorexia and constipation.

    From the endocrine system: increased libido, dysmenorrhea.

    From the urinary system: difficulty urinating, urinary retention in patients with prostatic hypertrophy.

    From the skin and mucous membranes: rash, increased sweating.

    Others: impaired vision, tachyphylaxis.

    Children have drowsiness.

    Overdose:

    Symptoms: possibly the appearance of nervous excitement, fever, insomnia, diarrhea, profuse sweating, nausea, vomiting, loss of appetite, circulatory disorders, limb tremors, dizziness, difficulty urinating.

    Ephedrine, used in high doses, leads to an increase in the level of sugar in the blood. The lethal oral dose of ephedrine is 1.0 g.

    Treatment: gastric lavage and the use of symptomatic agents.

    Interaction:

    Bronchocin® can be used simultaneously with antibiotics, antipyretic drugs and vitamins.

    Due to the presence of ephedrine in the formulation, it is necessary to keep in mind its drug interactions: it weakens the effects of narcotic and hypnotic drugs. When used simultaneously with cardiac glycosides, quinidine, tricyclic antidepressants, the risk of arrhythmias increases. With simultaneous application with reserpine and monoamine oxidase inhibitors, a sharp increase in blood pressure may be possible, with non-selective beta-blockers - a decrease in bronchodilator action. Reduces the effect of sympatholytic drugs.

    There is no evidence of adverse drug interactions between glaucin and other drugs.

    Special instructions:

    It is not recommended to prescribe the drug to people with diabetes, because ephedrine, used in doses exceeding therapeutic, increases the metabolism, thus leading to an increase in blood sugar levels.

    When using the drug should take into account that 1 measuring spoon - 5 ml contains up to 0.069 g of ethanol (96% - 1.7% by volume)

    Effect on the ability to drive transp.cf. and fur:

    It is necessary to refrain from driving vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions, due to the possible occurrence of dizziness and visual impairment.

    Form release / dosage:

    Syrup.

    Packaging:For 125 g in bottles of brown glass or brown bottles of polyethylene terephthalate. Each bottle, along with instructions for use and a measuring spoon for 5 ml is placed in a separate cardboard pack.
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children!

    Shelf life:

    4 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014278 / 01
    Date of registration:10.04.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:Balkanfarm - Troyan ADBalkanfarm - Troyan AD Bulgaria
    Manufacturer: & nbsp
    Representation: & nbspAktavis, Open Company Aktavis, Open Company
    Information update date: & nbsp09.03.2017
    Illustrated instructions
      Instructions
      Up